Advertisement

Topics

Glenmark Pharma Reports Positive Data In A Phase IIa Study Of GBR 830 For The Treatment Of Patients With Atopic Dermatitis

20:00 EDT 30 Jul 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Glenmark Pharma Reports Positive Data In A Phase IIa Study Of GBR 830 For The Treatment Of Patients With Atopic Dermatitis

NEXT ARTICLE

More From BioPortfolio on "Glenmark Pharma Reports Positive Data In A Phase IIa Study Of GBR 830 For The Treatment Of Patients With Atopic Dermatitis"

Quick Search
Advertisement